

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
SCOPE OF REPORT.....	1
METHODOLOGY AND INFORMATION SOURCES.....	2
INTENDED AUDIENCE.....	2
ANALYST CREDENTIALS.....	2
RELATED REPORTS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, THROUGH 2015 (\$ BILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, 2009-2015 (\$ BILLIONS)</i>	6
 CHAPTER THREE: INTRODUCTION.....	 7
HISTORICAL OVERVIEW.....	7
SCIENTIFIC BREAKTHROUGHS IN MENTAL HEALTH RESEARCH.....	8
DRIVERS AND CHALLENGES OF THE MENTAL HEALTH PHARMACEUTICAL MARKET.....	8
MENTAL HEALTH ORGANIZATIONS.....	9
CITIZENS COMMISSION ON HUMAN RIGHTS (CCHR).....	9
NATIONAL ALLIANCE OF MENTAL ILLNESS (NAMI).....	10
MENTAL HEALTH AMERICA (MHA).....	10
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH).....	10
GENERAL OVERVIEW OF THE MENTAL HEALTH PHARMACEUTICAL MARKET.....	10
<i>TABLE 1 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG CATEGORY, 2010 (%)</i>	11
<i>FIGURE 1 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG CATEGORY, 2010 (%)</i>	11
GENERAL OVERVIEW OF THE MENTAL ... (CONTINUED).....	12
DIAGNOSTICS FOR MENTAL ILLNESSES.....	13
OVERVIEW.....	13
Overview (Continued).....	14
<i>TABLE 2 U.S. LIFETIME PREVALENCE OF MENTAL HEALTH DISORDERS BY TYPE OF ILLNESS, 2009 (%)</i>	15
GENETIC FACTORS OF MENTAL HEALTH DISORDERS AND BIOMARKER DEVELOPMENT.....	15
<i>TABLE 3 GENETIC FACTORS ASSOCIATED WITH MENTAL HEALTH DISORDERS AND CURRENT DIAGNOSTIC TESTS</i>	16

Bipolar Disorder	16
<i>TABLE 4 RISK OF DEVELOPING BIPOLAR DISORDER BASED ON FAMILIAL RELATIONSHIP (%)</i>	16
ANK3/CACNA1C Gene Candidates	17
GRK3	17
New Diagnostic Tools for Bipolar Disorder Based on Genetic Findings.....	17
Schizophrenia	18
<i>TABLE 5 U.S. STATISTICAL RISK OF DEVELOPING SCHIZOPHRENIA BASED ON FAMILIAL RELATIONSHIP (%)</i>	18
Chromosomal Deletions.....	18
CMYA 5	19
New Diagnostics for Schizophrenia.....	19
Depression.....	19
New Diagnostics for Depression.....	20
BIOMARKER MARKET FOR CNS DISORDERS.....	21
<i>TABLE 6 GLOBAL MARKET FORECAST FOR BIOMARKERS FOR CNS DISORDERS AND DIAGNOSTICS TESTS, THROUGH 2015 (\$ MILLIONS)</i>	21
Recent Examples of Biomarker Research Development for Mental Disorders.....	22
Examples of Industry-Academia Collaborations as Drivers of Biomarker Development	23
PSYCHOTHERAPY FOR THE TREATMENT OF MENTAL DISORDERS	24
<i>TABLE 7 U.S. PSYCHOTHERAPY TREATMENT STATISTICS, 2009</i>	24
CHAPTER FOUR: DEPRESSION AND THE ANTIDEPRESSANTS DRUG MARKET	25
DEPRESSIVE DISORDER.....	25
DIAGNOSIS OF DEPRESSION	26
CURRENT DEPRESSION STATISTICS	26
<i>TABLE 8 U.S. DEPRESSIVE DISORDER STATISTICS, 2010</i>	27
TREATMENT OPTIONS FOR DEPRESSION	27
<i>TABLE 9 CURRENT TREATMENT OPTIONS FOR DEPRESSION</i>	28
ANTIDEPRESSANT DRUGS AS A MEDICAL TREATMENT FOR DEPRESSION	28
<i>TABLE 10 MAJOR ANTIDEPRESSANT DRUG CATEGORIES</i>	29
Major Types of Antidepressants	29
Selective Serotonin Reuptake Inhibitors (SSRIs).....	29
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs).....	29
Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs/Non Tricyclic Antidepressant).....	29
Tricyclic/Tetracyclic Antidepressants (TCAs).....	30

Monoamine Oxidase Inhibitors (MAOIs)	30
<i>TABLE 11 RATING OF COMMONLY USED ANTIDEPRESSANTS ACCORDING TO EFFICACY AND ACCEPTABILITY</i>	31
<i>TABLE 12 GLOBAL NET SALES FOR LEXAPRO, PRESTIQ, AND CYMBALTA, THROUGH 2015 (\$ BILLIONS)</i>	32
Monoamine ... (Continued)	33
<i>TABLE 13 AVERAGE ANNUAL ANTIDEPRESSANT PRESCRIPTIONS IN THE U.S., 2009 (MILLIONS)</i>	34
NEW ANTIDEPRESSANT DRUG DEVELOPMENT	34
<i>TABLE 14 CURRENT DRUG PIPELINES FOR ANTIDEPRESSANTS, 2010</i>	34
<i>TABLE 14 (CONTINUED)</i>	35
<i>TABLE 14 (CONTINUED)</i>	36
ANTIDEPRESSANT MARKET PARTICIPANTS ANALYSIS AND FORECAST	36
<i>TABLE 15 GLOBAL ANTIDEPRESSANT MARKET SHARES BY COMPANY, 2010 AND 2015 (%)</i>	37
<i>FIGURE 2 GLOBAL ANTIDEPRESSANT MARKET SHARES BY COMPANY, 2010 AND 2015 (%)</i>	37
NEW AREAS OF ANTIDEPRESSANT RESEARCH	38
KETAMINE	38
SCOPOLAMINE.....	39
CHAPTER FIVE: ANTIPSYCHOTICS MEDICATION MARKET.....	40
OVERVIEW	40
<i>TABLE 16 GLOBAL MARKET ANALYSIS OF LEADING ANTIPSYCHOTIC MEDICATIONS, 2008 AND 2009 (\$ BILLIONS)</i>	40
NEW ANTIPSYCHOTIC DRUGS	41
FANAPT	41
SAPHRIS	41
INVEGA SUSTENNA	41
<i>TABLE 17 GLOBAL MARKET SHARES OF LEADING ANTIPSYCHOTIC MEDICATIONS BY COMPANY, 2010 AND 2015 (%)</i>	42
<i>TABLE 17 (CONTINUED)</i>	43
<i>FIGURE 3 GLOBAL MARKET SHARES OF LEADING ANTIPSYCHOTIC MEDICATIONS BY COMPANY, 2010 AND 2015 (%)</i>	43
Invega Sustenna (Continued)	44
CHAPTER SIX: ANXIETY DISORDERS AND THE DRUG MARKET FOR ANXIOLYTICS	45
OVERVIEW	45
<i>TABLE 18 PREVALENCE OF ANXIETY DISORDERS IN THE U.S., 2010 (%)</i>	46

<i>TABLE 19 MEDICATION TREATMENTS FOR ANXIETY DISORDERS</i>	46
TYPES OF ANTIANXIETY MEDICATIONS	47
ANTIDEPRESSANTS	47
BENZODIAZEPINES	47
BETA-BLOCKERS	47
BUSPAR (BUSIPRONE).....	47
<i>TABLE 20 BENZODIAZEPINES USAGE STATISTICS, 2010 (%)</i>	48
XANAX.....	48
<i>TABLE 21 AVERAGE ANNUAL U.S. SALES OF XANAX AND BUSPAR,</i> <i>2010 (\$ MILLIONS)</i>	49
NON-BENZODIAZEPINE DRUG CANDIDATES AS ANXIOLYTICS.....	49
Adiplon or NG2-73.....	49
CGS-9896	49
Stresam (Etifoxine).....	49
Pagoclone	50
ADDITIONAL TREATMENT OPTIONS FOR ANXIETY DISORDERS	50
CURRENT DRUG PIPELINES FOR ANTIANXIETY DRUGS	50
<i>TABLE 22 CURRENT DRUG PIPELINES FOR ANXIETY</i> <i>TREATMENTS, 2010</i>	51
NEW PRECLINICAL INDICATIONS IN DRUG DEVELOPMENT FOR ANXIETY DISORDERS	52
XBD-173/AC-5216.....	52
BNC210.....	52
CXB722	53
CHAPTER SEVEN: SCHIZOPHRENIA	54
OVERVIEW.....	54
<i>TABLE 23 U.S. PREVALENCE OF SCHIZOPHRENIA AND</i> <i>HEALTHCARE COSTS, 2009</i>	54
<i>TABLE 24 STATISTICS FOR NIH RESEARCH FUNDING IN VARIOUS</i> <i>AREAS OF SCIENCE IN THE U.S., 2011 (\$)</i>	55
DIAGNOSIS OF SCHIZOPHRENIA	55
TREATMENT OF SCHIZOPHRENIA.....	56
<i>TABLE 25 CURRENT TREATMENTS FOR SCHIZOPHRENIA AND</i> <i>THEIR EFFICACY</i>	57
SEROQUEL AND ABILIFY AS REPRESENTATIVE OF THE DRUG MARKET FOR SCHIZOPHRENIA	57
SEROQUEL.....	57
ABILIFY	58
<i>TABLE 26 GLOBAL SALES OF SEROQUEL AND ABILIFY, THROUGH</i> <i>2015 (\$ BILLIONS)</i>	59
NEW DRUGS ON THE MARKET FOR THE TREATMENT OF SCHIZOPHRENIA	59
FANAPT (ILOPERIDONE)	59

SAPHRIS (ASENAPINE).....	59
NEW DRUG CANDIDATES IN DEVELOPMENT	60
<i>TABLE 27 CURRENT DRUG PIPELINES FOR SCHIZOPHRENIA</i>	
<i>TREATMENTS, 2010</i>	60
<i>TABLE 27 (CONTINUED)</i>	61
EXAMPLES OF NEW COMPOUNDS IN DEVELOPMENT	61
LY2140023	61
Latuda (Lurasidone) -- Recently Approved for	
Schizophrenia	61
Preclinical Trials on Compounds that Target the	
Glutamate System.....	62
EXAMPLES OF COLLABORATIONS IN SCHIZOPHRENIA	
RESEARCH.....	62
NEWMEDS (New Medications in Depression and	
Schizophrenia).....	62
Cypress Bioscience/BioLineRx	62
Janssen Pharmaceutical/Vanderbilt University	
program.....	63
Drugs Currently on the Market Testing for the New	
Indication of Schizophrenia	63
MARKET ANALYSIS OF THE SCHIZOPHRENIA DRUG MARKET	63
<i>TABLE 28 GLOBAL COMPANY SHARES OF ONGOING CLINICAL</i>	
<i>TRIALS FOR SCHIZOPHRENIA DRUG TREATMENTS, 2010</i>	
<i>(NUMBER/%)</i>	64
 CHAPTER EIGHT: CHILDHOOD AND ADOLESCENT MENTAL	
DISORDERS.....	65
OVERVIEW.....	65
<i>TABLE 29 PREVALENCE OF MENTAL DISORDERS IN CHILDREN</i>	
<i>AND ADOLESCENTS IN THE U.S., 2010</i>	65
TYPES OF MENTAL DISORDERS.....	66
ADHD (ATTENTION DEFICIT HYPERACTIVITY DISORDER).....	66
ADHD Treatments.....	66
<i>TABLE 30 DRUG TREATMENTS FOR ADHD</i>	67
Market Analysis for ADHD Treatments.....	67
<i>TABLE 31 NET SALES OF VYVANSE AND STRATTERA IN THE U.S.,</i>	
<i>THROUGH 2015 (\$ MILLIONS)</i>	68
ADHD Drug Market for Adults.....	69
<i>TABLE 32 U.S. STATISTICS FOR ADHD IN ADULTS, 2010</i>	69
New Drug Developments for ADHD Treatments.....	70
<i>TABLE 33 CURRENT DRUG PIPELINES FOR ADHD, 2010</i>	70
Alternative and New Treatments for ADHD	71
Neurofeedback/EEG	
(Electroencephalogram)/Biofeedback.....	71
Green Time Activities	71

Behavior Therapy and Homeopathic Remedies	71
AUTISM SPECTRUM DISORDER.....	72
<i>TABLE 34 U.S. AUTISM STATISTICS, 2009</i>	73
Treatment of Autism	73
<i>TABLE 35 CURRENT MEDICATIONS FOR AUTISM</i>	73
New Treatments for Autism.....	74
<i>TABLE 36 CURRENT DRUG PIPELINES FOR AUTISM</i> <i>TREATMENTS, 2010</i>	74
KM-391	74
STK-209 (Arbaclofen).....	74
CM-AT	75
 CHAPTER NINE: BIPOLAR DISORDER.....	76
OVERVIEW.....	76
<i>TABLE 37 U.S. BIPOLAR DISORDER STATISTICS, 2010</i>	76
CAUSES OF BIPOLAR DISORDER AND DIAGNOSIS	76
BIPOLAR DISORDER TREATMENTS	77
<i>TABLE 38 CURRENT DRUG TREATMENTS FOR BIPOLAR</i> <i>DISORDER</i>	77
ANXYOLITICS.....	78
ANTYPSYCHOTICS	78
MOOD STABILIZERS	78
OFF-LABEL DRUG TREATMENTS FOR BIPOLAR DISORDER.....	78
<i>TABLE 39 OFF-LABEL MEDICATIONS FOR BIPOLAR DISORDER</i>	79
Anticonvulsants	79
ABS-103	79
Topamax.....	79
Mood Stabilizers	80
Neorontin	80
Tegretol	80
Antidepressant (Lamictal)	80
DRUGS UNDER INVESTIGATION TO TREAT BIPOLAR DISORDER.....	80
Zyprexa.....	80
Seroquel	80
NEW DRUG DEVELOPMENTS TO TREAT BIPOLAR DISORDER.....	81
SAPHRIS	81
SUBSTANCE P-BLOCKERS.....	81
<i>TABLE 40 CURRENT DRUG PIPELINES FOR BIPOLAR DISORDER</i> <i>TREATMENTS, 2010</i>	82
MARKET ANALYSIS OF BIPOLAR DISORDER DRUGS	82
<i>TABLE 41 GLOBAL MARKET FOR DRUGS TO TREAT BIPOLAR</i> <i>DISORDER, THROUGH 2015 (\$ BILLIONS)</i>	83

CHAPTER TEN: EATING DISORDERS	84
OVERVIEW	84
<i>TABLE 42 U.S. EATING DISORDER STATISTICS, 2010</i>	84
TYPES OF EATING DISORDERS	85
ANOREXIA NERVOSA	85
BINGE EATING	85
BULIMIA NERVOSA	86
OBESITY	86
EATING DISORDER TREATMENTS	86
<i>TABLE 43 CURRENT DRUG TREATMENTS FOR EATING DISORDERS</i>	86
ECONOMIC COSTS OF TREATING EATING DISORDERS	87
<i>TABLE 44 AVERAGE COST OF TREATING EATING DISORDERS IN THE U.S., 2010</i>	87
NEW DRUG DEVELOPMENTS FOR EATING DISORDERS	88
<i>TABLE 45 CURRENT DRUG PIPELINES FOR EATING DISORDER TREATMENTS, 2010</i>	88
<i>TABLE 45 (CONTINUED)</i>	89
 CHAPTER ELEVEN: COGNITIVE DISORDERS AS MENTAL HEALTH ILLNESSES	 90
OVERVIEW	90
<i>TABLE 46 GLOBAL DEMENTIA AND DELIRIUM STATISTICS, 2010</i>	90
DEMENTIA	90
TYPES OF ILLNESS-RELATED DEMENTIA	91
Alzheimer's-Related Dementia	91
Vascular Dementia	91
Parkinson's-Related Dementia	92
<i>TABLE 47 U.S. PREVALENCE OF ALZHEIMER'S AND PARKINSON'S DISEASE AND TREATMENT COSTS, 2010 (\$ BILLIONS)</i>	92
DRUGS FOR TREATING DEMENTIA	92
<i>TABLE 48 CURRENT TREATMENTS FOR DEMENTIA</i>	93
Acetylcholinesterase Inhibitors	93
N-methyl-D Aspartate Blockers	93
Clioquinol	93
Eldepryl (Selegeline)	94
Additional Treatments	94
ALZHEIMER'S AS THE MOST PROFITABLE MARKET FOR DEMENTIA TREATMENTS	94
<i>TABLE 49 GLOBAL ALZHEIMER'S DRUG MARKET, THROUGH 2015 (\$ BILLIONS)</i>	95
<i>TABLE 50 GLOBAL NET SALES OF NAMENDA AND ARICEPT, THROUGH 2015 (\$ BILLIONS)</i>	95

<i>TABLE 51 DRUG PIPELINES FOR DEMENTIA BY RELATED CONDITION/INDICATION: ALZHEIMER'S, COGNITIVE DISORDERS, AND SCHIZOPHRENIA, 2010</i>	96
<i>TABLE 51 (CONTINUED)</i>	97
<i>TABLE 51 (CONTINUED)</i>	98
PARKINSON'S AS A POTENTIAL MARKET FOR DEMENTIA TREATMENTS	99
<i>TABLE 52 GLOBAL NET SALES OF MITAPEX AND REQUIP, 2007– 2009 (\$ MILLIONS)</i>	99
DELIRIUM.....	100
AMNESIA.....	100
<i>TABLE 53 TYPES AND CAUSES OF AMNESIA</i>	101
EPILEPSY-RELATED DEFICITS IN COGNITION.....	102
<i>TABLE 54 GLOBAL EPILEPSY AND ANTI-SEIZURE TREATMENT MARKET ANALYSIS, 2010 (\$ BILLIONS/%)</i>	102
<i>TABLE 55 GLOBAL ESTIMATED EPILEPSY/ANTI-SEIZURE DRUG MARKET, THROUGH 2015 (\$ BILLIONS)</i>	103
<i>TABLE 56 CURRENT DRUG/DEVICE PIPELINES FOR EPILEPSY TREATMENTS, 2010</i>	104
MEMORY ENHANCEMENT MEDICATION (NOOTROPICS).....	104
MEMORY ENHANCEMENT MEDICATION ... (CONTINUED)	105
MEMORY ENHANCEMENT MEDICATION ... (CONTINUED)	106
CHAPTER TWELVE: SUBSTANCE AND ALCOHOL ADDICTIONS AS MENTAL HEALTH DISORDERS.....	107
OVERVIEW.....	107
<i>TABLE 57 U.S. DRUG/ALCOHOL ABUSE TREATMENT STATISTICS, 2010 (MILLIONS)</i>	107
ECONOMIC COSTS OF ALCOHOL AND DRUG ABUSE	107
<i>TABLE 58 ECONOMIC COST OF SUBSTANCE ABUSE IN THE U.S., 2010 (\$ BILLIONS)</i>	108
MEDICATIONS AND TREATMENT FOR DRUG/ALCOHOL ABUSE	108
<i>TABLE 59 CURRENT MEDICATIONS USED IN THE TREATMENT OF SUBSTANCE ABUSE</i>	109
TYPES OF ADDICTIONS AND THEIR TREATMENT OPTIONS	109
SUBSTANCE ABUSE MARKET ANALYSIS	110
<i>TABLE 60 GLOBAL NET SALES OF VIVITROL, THROUGH 2015 (\$ MILLIONS)</i>	110
NEW DRUG DEVELOPMENTS FOR THE TREATMENT OF SUBSTANCE ABUSE	111
<i>TABLE 61 DRUG PIPELINES FOR SUBSTANCE ABUSE TREATMENTS BY CONDITION, 2010</i>	111
<i>TABLE 61 (CONTINUED)</i>	112

CHAPTER THIRTEEN: PERSONALITY DISORDERS	113
OVERVIEW	113
<i>TABLE 62 U.S. PREVALENCE OF PERSONALITY DISORDERS WITH</i>	
<i>DESCRIPTIONS, 2007</i>	113
<i>TABLE 62 (CONTINUED)</i>	114
TREATMENTS FOR PERSONALITY DISORDERS.....	114
NEW DRUG DEVELOPMENTS FOR PERSONALITY DISORDERS	115
<i>TABLE 63 CURRENT DRUG PIPELINES FOR THE TREATMENT OF</i>	
<i>PERSONALITY DISORDERS, 2010</i>	115
 CHAPTER FOURTEEN: SLEEP DISORDERS AS MENTAL HEALTH	
CONDITIONS	116
OVERVIEW	116
<i>TABLE 64 U.S. PREVALENCE OF SLEEP DISORDERS AND</i>	
<i>HEALTHCARE COSTS, 2010</i>	117
TREATMENTS FOR SLEEP DISORDERS	117
<i>TABLE 65 CURRENT MEDICATIONS FOR SLEEP DISORDERS</i>	118
<i>TABLE 66 GLOBAL SLEEP DISORDER DRUG SALES BY MARKET</i>	
<i>LEADERS, 2009 (\$ MILLIONS)</i>	118
NEW DRUG PIPELINES FOR THE TREATMENT OF SLEEP	
DISORDERS	119
<i>TABLE 67 DRUG PIPELINES FOR SLEEP DISORDER TREATMENTS,</i>	
<i>2010</i>	119
NEW DRUG PIPELINES FOR (CONTINUED)	ERROR! BOOKMARK NOT DEFINED
 CHAPTER FIFTEEN: ADDITIONAL MARKETS FOR DRUGS TO TREAT	
MENTAL DISORDERS.....	121
FRAGILE X SYNDROME	121
PREMENSTRUAL SYNDROME	121
<i>TABLE 68 DRUG PIPELINES FOR VARIOUS MENTAL CONDITIONS,</i>	
<i>2010</i>	122
 CHAPTER SIXTEEN: MENTAL HEALTH PHARMACEUTICAL MARKETS	
BY GEOGRAPHIC REGION	123
ANTIDEPRESSANTS MARKETED IN JAPAN	123
<i>TABLE 69 ANTIDEPRESSANT DRUGS MARKETED IN JAPAN, 1999-</i>	
<i>2011</i>	123
ANTIDEPRESSANTS MARKETED ... (CONTINUED).....	124
<i>TABLE 70 GLOBAL ANTIDEPRESSANT MARKET SHARE FORECAST</i>	
<i>BY GEOGRAPHIC REGION, 2010 AND 2015 (%)</i>	125
<i>FIGURE 4 GLOBAL ANTIDEPRESSANT MARKET SHARE FORECAST</i>	
<i>BY GEOGRAPHIC REGION, 2010 AND 2015</i>	126
MENTAL HEALTH DRUGS MARKETED IN OTHER GEOGRAPHIC	
REGIONS.....	126

<i>TABLE 71 GLOBAL MARKET SHARES OF VARIOUS TYPES OF MENTAL HEALTH DRUGS BY GEOGRAPHIC REGION, 2010 (%)</i>	126
<i>FIGURE 5 GLOBAL MARKET SHARES OF VARIOUS TYPES OF MENTAL HEALTH DRUGS BY GEOGRAPHIC REGION, 2010 (%)</i>	127
CHAPTER SEVENTEEN: EXAMPLES OF ECONOMIC COSTS IN TREATING MENTAL DISORDERS	128
<i>TABLE 72 U.S. AVERAGE ANNUAL HEALTHCARE COSTS PER PATIENT WITH BIPOLAR DISORDER, 2010 (\$/%)</i>	128
<i>TABLE 73 U.S. COSTS OF TREATING ADHD, 2010</i>	129
CHAPTER EIGHTEEN: LEGAL ISSUES AND LAWSUITS IN THE PHARMACEUTICAL INDUSTRY FOR MENTAL DISORDERS	130
<i>TABLE 74 RECENT EXAMPLES OF MENTAL HEALTH DRUG COMPANY LAWSUITS, 2007-2010 (\$ MILLIONS)</i>	130
DRUGS INVOLVED IN LITIGATION	130
ZYPREXA	130
SEROQUEL.....	131
ABILIFY	131
RISPERDAL	132
CHAPTER NINETEEN: MARKET SUMMARY	133
OVERVIEW	133
<i>TABLE 75 GLOBAL MENTAL HEALTH PHARMACEUTICALS BY DRUG CATEGORY, THROUGH 2015 (\$ BILLIONS)</i>	134
<i>FIGURE 6 GLOBAL MENTAL HEALTH PHARMACEUTICALS BY DRUG CATEGORY, 2009-2015 (\$ BILLIONS)</i>	134
OVERVIEW (CONTINUED)	135
NEW PIPELINES AS A FORECAST OF MARKET DEVELOPMENT	136
<i>TABLE 76 ANALYSIS OF CURRENT DRUG PIPELINES IN THE MENTAL HEALTH PHARMACEUTICAL INDUSTRY (NUMBER/%)</i>	136
MAJOR MARKET PARTICIPANTS IN THE MENTAL HEALTH PHARMACEUTICAL INDUSTRY	136
PFIZER	137
ELI LILLY	137
GLAXOSMITHKLINE	137
ASTRAZENECA	137
BRISTOL-MYERS SQUIBB	137
JOHNSON & JOHNSON.....	138
SELECTED COMPANY PROFILES	138
ASTRAZENECA	138
BRISTOL-MYERS SQUIBB	139
ELI LILLY AND CO.....	140
GLAXOSMITHKLINE, PLC.....	141
JOHNSON & JOHNSON.....	142

PFIZER, INC.	143
LIST OF COMPANIES DISCUSSED IN REPORT	144
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	145
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	146
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	147
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	148
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	149
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	150
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	151
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	152
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	153
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	154
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	155
LIST OF COMPANIES DISCUSSED ... (CONTINUED)	156
APPENDIX ONE: ACRONYMS.....	157
APPENDIX TWO: LIST OF ADDITIONAL SOURCES	158
LIST OF ADDITIONAL SOURCES.....	158
LIST OF ADDITIONAL SOURCES (CONTINUED)	159